News about "Syngene International bioconjugation suite"

Syngene International Announces Plans to Add Bioconjugation Suite for End-To-End Antibody-Drug Conjugates Development

Syngene International Announces Plans to Add Bioconjugation Suite for End-To-End Antibody-Drug Conjugates Development

With this new capability, Syngene will offer fully integrated, end-to-end services for antibody-drug conjugates (ADCs) – from discovery through to GMP manufacturing – placing it among a handful of CDMOs with full-service capabilities.

Syngene International Bioconjugation Suite | 24/10/2025 | By Darshana 117


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members